Young H. Park

Mokdong, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

Journal: British journal of haematology

Published: March 19, 2026

Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.

Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.

Journal: Haematologica

Published: February 24, 2026

Short term real-world effectiveness of faricimab in neovascular age-related macular degeneration patients in the Republic of Korea.

Short term real-world effectiveness of faricimab in neovascular age-related macular degeneration patients in the Republic of Korea.

Journal: Scientific reports

Published: December 16, 2025

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry.

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry.

Journal: Blood cancer journal

Published: October 31, 2025

Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b.

Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b.

Journal: Therapeutic advances in hematology

Published: October 05, 2025

α-Crystallins and vascular endothelial growth factor in aqueous humor of patients with neovascular age-related macular degeneration.

α-Crystallins and vascular endothelial growth factor in aqueous humor of patients with neovascular age-related macular degeneration.

Journal: Japanese journal of ophthalmology

Published: September 25, 2025

Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 24, 2025

Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin's lymphoma.

Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin's lymphoma.

Journal: Blood research

Published: July 04, 2025

Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera.

Efficacy and Safety of Ropeginterferon Alfa-2b in Low-Risk Polycythemia Vera.

Journal: Cancer research and treatment

Published: May 23, 2025

Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study.

Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 09, 2025

Correction: Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Correction: Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.

Journal: Blood research

Published: April 08, 2025

Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study.

Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study.

Journal: Haematologica

Published: March 22, 2025

Showing 1-12 of 73

Last Updated: 09/26/2026